Apollomics Stock Forward View - Polynomial Regression
| APLM Stock | 19.80 0.00 0.00% |
Momentum
Impartial
Oversold | Overbought |
Wall Street Target Price 2 | Quarterly Revenue Growth 2.623 |
This section provides headline-driven context for Apollomics Class A alongside peer activity.
The Polynomial Regression forecasted value of Apollomics Class A on the next trading day is expected to be 21.26 with a mean absolute deviation of 0.89 and the sum of the absolute errors of 54.27.Apollomics after-hype prediction price | $ 19.45 |
The sentiment panel provides context that can be compared with forecasting models and technical indicators.
Apollomics | Build AI portfolio with Apollomics Stock |
Apollomics Additional Predictive Modules
Most predictive techniques to examine Apollomics price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Apollomics using various technical indicators. When you analyze Apollomics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Polynomial Regression Price Forecast For the 14th of March 2026
Given 90 days horizon, the Polynomial Regression forecasted value of Apollomics Class A on the next trading day is expected to be 21.26 with a mean absolute deviation of 0.89 , mean absolute percentage error of 1.23 , and the sum of the absolute errors of 54.27 .Please note that although there have been many attempts to predict Apollomics Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Apollomics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Apollomics | Apollomics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Apollomics Class A uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Polynomial Regression forecasting method's relative quality and the estimations of the prediction error of Apollomics stock data series using in forecasting. Note that when a statistical model is used to represent Apollomics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 118.32 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.8896 |
| MAPE | Mean absolute percentage error | 0.0461 |
| SAE | Sum of the absolute errors | 54.2657 |
The mean reversion effect in Apollomics is stronger when the initial deviation was driven by sentiment rather than fundamental change. Identifying the root cause of Apollomics' price dislocation is essential before acting.
After-Hype Price Density Analysis
The probability distribution for Apollomics' predicted price encodes the full spectrum of outcomes, weighted by their estimated likelihood. Investors should compare this range against their personal risk tolerance before committing to Apollomics positions.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The news prediction model for Apollomics analyzes the correlation between Apollomics' historical headline events and same-day or next-day price movements. Apollomics' after-hype downside and upside margins for the prediction period are 13.99 and 24.91, respectively. Predictive accuracy varies significantly across different news categories and market regimes for Apollomics.
Current Value
The after-hype framework applied to Apollomics Class A assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Apollomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apollomics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Apollomics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.48 | 5.46 | 0.35 | 0.05 | 2 Events | 5 Events | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
19.80 | 19.45 | 1.77 |
|
Hype Timeline
Apollomics Class A is presently traded for 19.80. The company has historical hype elasticity of -0.35, and average elasticity to hype of competition of -0.05. Apollomics is expected to decline in value after the next headline, with the price expected to drop to 19.45. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -1.77%, whereas the daily expected return is presently at 0.48%. The volatility of related hype on Apollomics is about 5200.0%, with the expected price after the next announcement by competition of 19.75. The company recorded a loss per share of 52.8. Apollomics Class A had not issued any dividends in recent years. The company completed a 1:100 stock split on 25th of November 2024. Given the investment horizon of 90 days the next expected press release will be in a few days. Historical Fundamental Analysis of Apollomics can be used to cross-verify projections for Apollomics. The historical series provides projection context.Related Hype Analysis
Sector-wide news events often affect Apollomics before the fundamental impact on Apollomics' own business becomes clear. Peer hype analysis helps investors distinguish between sector-level sentiment shifts and Apollomics-specific developments.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ICU | SeaStar Medical Holding | -0.05 | 10 per month | 0.00 | -0.04 | 9.58 | -8.56 | 34.66 | |
| MBRX | Moleculin Biotech | 0.1 | 9 per month | 0.00 | -0.18 | 7.73 | -10.18 | 56.02 | |
| ATHA | Athira Pharma | -0.60 | 5 per month | 3.97 | 0.13 | 9.87 | -8.06 | 72.52 | |
| LNAI | Lunai Bioworks | 0.13 | 8 per month | 0.00 | -0.27 | 10.23 | -11.94 | 63.82 | |
| THAR | Tharimmune | 0.05 | 10 per month | 5.44 | 0.14 | 11.15 | -9.23 | 29.73 | |
| BLRX | BioLineRx | -0.04 | 2 per month | 0.00 | -0.12 | 4.17 | -4.89 | 10.49 | |
| ADAP | Adaptimmune Therapeutics Plc | -0.01 | 6 per month | 15.04 | 0.03 | 22.82 | -18.18 | 168.52 | |
| LPTX | Leap Therapeutics | 0.01 | 9 per month | 6.90 | 0.14 | 25.00 | -9.43 | 65.13 | |
| GOVX | GeoVax Labs | 0.21 | 8 per month | 0.00 | -0.22 | 11.16 | -13.98 | 48.30 | |
| ANL | Adlai Nortye Ltd | -0.85 | 11 per month | 4.69 | 0.27 | 25.00 | -12.79 | 102.66 |
Other Forecasting Options for Apollomics
For both new and experienced investors in Apollomics, the ability to analyze Apollomics' price movement is a fundamental investment skill. Price chart noise in Apollomics Stock can create false signals and mislead investment decisions.Apollomics Related Equities
The following equities are related to Apollomics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Apollomics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Apollomics Market Strength Events
Tracking market strength indicators for Apollomics helps investors understand the momentum dynamics of the stock in real time. These signals support informed decisions about when to enter or exit positions in Apollomics Class A for maximum return potential.
| Accumulation Distribution | 0.0289 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 20.1 | |||
| Day Typical Price | 20.0 | |||
| Market Facilitation Index | 0.59 | |||
| Price Action Indicator | -0.29 | |||
| Relative Strength Index | 52.43 |
Apollomics Risk Indicators
Properly assessing Apollomics' risk indicators is a prerequisite for building reliable price forecasts. Identifying and quantifying the risks associated with Apollomics' allows investors to make better-informed decisions about accepting or hedging their exposure.
| Mean Deviation | 4.23 | |||
| Semi Deviation | 4.27 | |||
| Standard Deviation | 5.55 | |||
| Variance | 30.75 | |||
| Downside Variance | 22.45 | |||
| Semi Variance | 18.26 | |||
| Expected Short fall | -4.95 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Apollomics
Coverage intensity for Apollomics Class A matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Apollomics Short Properties
Short sentiment tied to Apollomics Class A matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 926.5 K | |
| Cash And Short Term Investments | 9.8 M |
More Resources for Apollomics Stock Analysis
A comprehensive view of Apollomics Class A starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Apollomics Class A Stock. Key reports that frame Apollomics Class A Stock are listed below:Historical Fundamental Analysis of Apollomics can be used to cross-verify projections for Apollomics. The historical series provides projection context. Analysis related to Apollomics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Earnings Share -52.80 | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
Understanding Apollomics Class A includes distinguishing between market value and book value, where book value reflects Apollomics's accounting equity. Apollomics' market capitalization is 44.92 M. With a P/B ratio of 8.15, the market values Apollomics well above its book equity. Enterprise value stands at 41.52 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Apollomics' value from its trading price, which are computed with different methods. For Apollomics, key inputs include a P/B ratio of 8.15, ROE of -2.34%, and revenue of 198 K. By contrast, market price reflects the level where buyers and sellers transact.